Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

11.82 -2.12 (-15.21%)
Streaming Delayed Price Updated: 3:54 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,829,183
Open 13.55
Bid (Size) 11.82 (2)
Ask (Size) 11.83 (11)
Prev. Close 13.94
Today's Range 11.82 - 13.80
52wk Range 3.520 - 23.40
Shares Outstanding 45,676,887
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’
Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval. 
Via Stocktwits
Exposures Product Safety
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-21.0%
-21.0%
1 Month
+61.9%
+61.9%
3 Month
-7.6%
-7.6%
6 Month
-17.6%
-17.6%
1 Year
+133.6%
+133.6%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
A Look Ahead: Capricor Therapeutics's Earnings Forecast
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Forecasting The Future: 5 Analyst Projections For Capricor Therapeutics
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
Via Benzinga
Exposures Product Safety
Earnings Scheduled For May 13, 2025
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic
Via Stocktwits
Topics Economy Government
Exposures Economy Political Product Safety
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
Via Talk Markets
Topics Stocks / Equities
FDA Advisory Committee Shakeup and Implications for Capricor Therapeutics
Via Talk Markets
Topics Government Stocks / Equities
Exposures Political Product Safety
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Capricor Therapeutics Stock Surges After Q4 Results Beat Estimates: Retail Gets More Bullish
Via Stocktwits
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
Via Benzinga
A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 Analysts
Via Benzinga
Earnings Scheduled For March 19, 2025
Via Benzinga

Frequently Asked Questions

Is Capricor Therapeutics, Inc. - Common Stock publicly traded?
Yes, Capricor Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Capricor Therapeutics, Inc. - Common Stock trade on?
Capricor Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Capricor Therapeutics, Inc. - Common Stock?
The ticker symbol for Capricor Therapeutics, Inc. - Common Stock is CAPR on the Nasdaq Stock Market
What is the current price of Capricor Therapeutics, Inc. - Common Stock?
The current price of Capricor Therapeutics, Inc. - Common Stock is 11.82
When was Capricor Therapeutics, Inc. - Common Stock last traded?
The last trade of Capricor Therapeutics, Inc. - Common Stock was at 06/13/25 03:54 PM ET
What is the market capitalization of Capricor Therapeutics, Inc. - Common Stock?
The market capitalization of Capricor Therapeutics, Inc. - Common Stock is 539.90M
How many shares of Capricor Therapeutics, Inc. - Common Stock are outstanding?
Capricor Therapeutics, Inc. - Common Stock has 540M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.